DelveInsight’s “Spinocerebellar Ataxias Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Spinocerebellar Ataxias market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Spinocerebellar Ataxias drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Spinocerebellar Ataxias treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Spinocerebellar Ataxias: An Overview
Spinocerebellar Ataxia (SCA) is a genetic disorder that is progressive, degenerative, and often fatal. The clinical marker of all SCAs is a progressive loss of balance and coordination accompanied by slurred speech. The mobility and communicative skills of individuals with an SCA are restricted, which strongly impairs quality of life, and many SCAs lead to premature death. Total 48 SCAs have been identified to date.
Genetically, the SCAs fall into two major groups: those caused by dynamic repeat expansion mutations (repeat expansion SCAs) and those caused by nonrepeating mutations. Further, repeat expansions are also a major cause of non-SCA inherited neurological diseases. There are at least 12 repeat expansion SCAs. Six of these diseases—SCA1, SCA2, SCA3/Machado–Joseph disease, SCA6, SCA7, and SCA17 are caused by translated CAG repeat expansion mutations that encode stretches of pure glutamine in the respective disease proteins; these diseases are thus referred to as polyglutamine SCAs. SCA3, also known as Machado-Joseph disease, is the most common type of SCA. SCA types 9 through 36 are rare and less well characterized.
Spinocerebellar Ataxias Market Key Facts
-
As per Bhandari et al. (2022), the global prevalence of spinocerebellar ataxia is 1 to 5 per 10,0000 and overall European prevalence is 0.9 to 3 per 10,0000 with some geographical variation i.e. 2/100000 in Italy.
-
According to Sullivan et al. 2019, the global prevalence of SCA is 3 in 100,000, however, a wide regional variation exists. SCA3 is the commonest subtype around the globe.
-
According to DelveInsight’s analysis, the type-specific epidemiology of SCA, dentatorubral-pallidoluysian atrophy (DRPLA) was found to be more common in Japan when compared with other countries.
-
According to Lin et al. (2020), the pooled prevalence of hereditary ataxia is ~2.7–38.35 per 100,000; therefore, SCAs are considered as orphan diseases.
Spinocerebellar Ataxias Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Spinocerebellar Ataxias pipeline therapies. It also thoroughly assesses the Spinocerebellar Ataxias market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Spinocerebellar Ataxias drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Spinocerebellar Ataxias Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Spinocerebellar Ataxias epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Spinocerebellar Ataxias epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Spinocerebellar Ataxias Epidemiology, Segmented as –
-
Total Prevalent cases of Spinocerebellar Ataxias [2019–2032]
-
Total Diagnosed Cases of Spinocerebellar Ataxias [2019–2032]
-
Type-Specific Cases of Spinocerebellar Ataxias [2019–2032]
-
Total Treated Cases of Spinocerebellar Ataxias [2019–2032]
Spinocerebellar Ataxias Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Spinocerebellar Ataxias market or expected to be launched during the study period. The analysis covers the Spinocerebellar Ataxias market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Spinocerebellar Ataxias drugs based on their sale and market share.
The report also covers the Spinocerebellar Ataxias pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Spinocerebellar Ataxias companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Spinocerebellar Ataxias Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-market
Spinocerebellar Ataxias Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Spinocerebellar Ataxias. Currently, Biohaven Pharmaceuticals is leading the therapeutics market with its Spinocerebellar Ataxias drug candidates in the most advanced stage of clinical development.
Spinocerebellar Ataxias Companies Actively Working in the Therapeutics Market Include
-
BioGene
-
Biohaven Pharmaceuticals
-
RETROTOPE
-
Seelos Therapeutics
-
Steminent Biotherapeutics
-
VICO Therapeutics
-
Wave Life Sciences
And Many Others
Emerging and Marketed Spinocerebellar Ataxias Therapies Covered in the Report Include:
-
Troriluzole: Biohaven Pharmaceuticals
-
Rovatirelin (KPS-0373): Kissei Pharmaceutical
-
IB1001: IntraBio
-
Stemchymal: Steminent Biotherapeutics
-
RT011: RETROTOPE
-
VO659: VICO Therapeutics
-
BIIB132: BioGene
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Spinocerebellar Ataxias Competitive Intelligence Analysis
4. Spinocerebellar Ataxias Market Overview at a Glance
5. Spinocerebellar Ataxias Disease Background and Overview
6. Spinocerebellar Ataxias Patient Journey
7. Spinocerebellar Ataxias Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Spinocerebellar Ataxias Treatment Algorithm, Current Treatment, and Medical Practices
9. Spinocerebellar Ataxias Unmet Needs
10. Key Endpoints of Spinocerebellar Ataxias Treatment
11. Spinocerebellar Ataxias Marketed Therapies
12. Spinocerebellar Ataxias Emerging Drugs and Latest Therapeutic Advances
13. Spinocerebellar Ataxias Seven Major Market Analysis
14. Attribute Analysis
15. Spinocerebellar Ataxias Market Outlook (In US, EU5, and Japan)
16. Spinocerebellar Ataxias Companies Active in the Market
17. Spinocerebellar Ataxias Access and Reimbursement Overview
18. KOL Views on the Spinocerebellar Ataxias Market
19. Spinocerebellar Ataxias Market Drivers
20. Spinocerebellar Ataxias Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
The global Hemostats market was valued at USD 3.64 billion in 2021, growing at a CAGR of 5.72% during the forecast period from 2023 to 2028 to reach USD 5.07 billion by 2028. The Hemostats market is expected to grow as a result of factors like the rise in surgical procedures, the increased emphasis on controlling blood loss during operations, and technological advancements in product development.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/